Complete if Known Substitute for form 1449A/PTO Application Number 10/709.801 INFORMATION DISCLOSURE Filing Date May 28, 2004 STATEMENT BY APPLICANT First Named Inventor Caroline Desponts (use as many sheets as necessary) Art Unit 1635 **Examiner Name** Jane J. Zara Sheet of Attorney Docket Number 1 2 USF 212X71T

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/JZ/	U1	US-2003/0114401 A1	06-19-2003	Bennett et al.	All
/.17/	U2	US-6,025,198	02-15-2000	Bennett et al.	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document			Pages, Columns, Lines,		
Examiner Initials*	Cite No. 1	Country Code 3 - Number 4 - Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T*	
	F1						
	F2						
	F3						
	F4						
	F5						
	F6						
	F7						

Signature	/Jane Zara/	Considered	10/22/2009	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 806. Draw line through citation finite in conformance and not considered include copy of this form with next communication to applicant: Applicant's unique citation designation cutation (policinal or USPTO Patient Documents at www.uscho.gov on MPEP90.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard T3). *For Japanese patient focuments, like indication of the year of the region of the Emperor must precede the senial number of the patient document with fixed of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Transitation is attacked.

.

This collection of information is required by 3T CFR 197 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is powered by 35 USC 1.22 and 3T CFR 1.14. This collection is estimated to late 2 Durist to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this budges, should be sent to the Chief Information Ories; U.S. Pathar and Trademark Office, P.O. Box 1450, Alexandria, VA. 2231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 4450, Alexandria, VA. 2231-1450.

if you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

2

2

Complete if Known		
Application Number	10/709,801	
Filing Date	May 28, 2004	
First Named Inventor	Caroline Desponts	
Group Art Unit	1635	
Examiner Name	Jane J. Zara	
Attorney Docket Number	USF 212XZ1T	

		NON PATENT LITERATURE DOCUMENTS	
		include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/JZ/	JZ/ HUBER, M. et al. "The role of SHIP in growth factor induced signalling" Progress in Biophysics Molecular Biology, 1999, pp. 423-434, Vol. 71.		
	R2	MURAILLE, E. et al. "Distribution of the Src-homology-2-domain-containing inositol 5-phosphatase SHIP-2 in both non-haemopoietic and haemopoietic cells and possible involvement of SHIP-2 in negative signaling of B-cells" <i>Biochem J.</i> , 1999, pp. 697-705, Vol. 342.	
	R3	PESESSE, X. et al. "The SHZ domain containing inositol 5-phosphatase SHIP2 displays phosphaltdylinositol 3,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate 5-phosphatase activity" <i>FEBS Letters</i> , 1998, pp. 301-303, Vol. 437.	
	R4	ROHRSCHNEIDER, L.R. et al. "Structure, function, and biology of SHIP proteins" Genes & Development, 2000, pp. 505-520, Vol. 14.	
	R5	SLY, L.M. et al. "SHIP, SHIP2, and PTEN activities are regulated in vivo by modulation of their protein levels: SHIP is up-regulated in macrophages and mast cells by lipopolysaccharide" Experimental Hematology, 2003, pp. 1170-1181, Vol. 31.	
	R6	WISNIEWSKI, D. et al. "Neoplasia: A Novel SH2-Containing Phosphatidylinositol 3.4,5- Trisphosphate 5-Phosphatase (SHIP2) Is Constitutively Tyrosine Phosphorylated and Associated With src Homologous and Collagen Gene (SHC) in Chronic Myelogenous Leukemia Progenitor Cells" Blood, April 1999, p. 2707-2720, Vol. 93, No. 8.	
	R7	Office Action mailed July 22, 2009 in U.S. Serial No. 10/904,667 filed November 22, 2004.	
	R8	Office Action mailed September 28, 2009 in U.S. Serial No. 11/451,004 filed June 12, 2006.	
$\overline{\Psi}$	R9	Notice of Allowance mailed October 7, 2009 in U.S. Serial No. 11/787,064 filed April 13, 2007.	
	R10		
	R11		1
	R12		

Examiner	/Jane Zara/	Date	10/22/2009
Signature	/ our to must de	Considered	10/22/2000

Signature

FAMMER Initial I reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered include copy of this form with less d communication to applicant.

FAMMER IN Considered include copy of this form with less d communication to applicant.

The confection of information is required by 37 CFR 19.8 The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S. 122 and 37 CFR 11.4. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. The will want operation the individual case Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patient and commissions for the VER of the VER Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.